DataMeds AI's free float is about 1.5 million shares. On Monday, the company agreed to sell about $7 million worth of new shares directly into the open market.
The arrangement works through Dawson James Securities, which will place shares gradually at prevailing prices rather than in a single block — a setup called an at-the-market offering. The agreement was signed on November 16; the company filed notice with regulators the next day.
Every new share issued makes the ones already out there worth a smaller slice of the same company. The filing does not say what DataMeds AI plans to do with the proceeds, or how quickly it intends to draw on the facility.
Shares closed 15.41% higher at $0.7390, on dollar volume of about $2.2 million.
The legal basis for the sale is a shelf registration the SEC declared effective in May. A shelf registration lets a company register securities in advance and then sell them in tranches over time, without filing a new prospectus for each sale. DataMeds AI filed the supplement for this specific offering on November 17.